Brief: RhoVac Reports Positive Interim Immune-Results In The Follow-Up Testing

Chosa Oncology AB

17/01/2019 14:16

Jan 17 (Reuters) - RhoVac AB  RHOVAC.TE :
    * RHOVAC REPORTS POSITIVE INTERIM IMMUNE-RESULTS IN THE
FOLLOW-UP
PHASE OF COMPANY'S PHASE I/II CLINICAL STUDY
    * RESULT SHOW THAT 18 OF 21 OF PATIENTS (86%) STILL HAVE A
ROBUST
IMMUNE RESPONSE TO RV001
    * PRIMARY ENDPOINT OF STUDY WAS TO EVALUATE SAFETY AND
TOLERABILITY OF RV001 CANCER VACCINE
    * FINAL RESULTS, INCLUDING 9- AND 12 MONTH'S FOLLOW-UP
IMMUNOLOGICAL ANALYSIS, IS EXPECTED TO BE REPORTED MID-2019.

Source text for Eikon:  ID:nWkrf58Ml 
Further company coverage:  RHOVAC.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))